UW Positve Research, Harborview Medical Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ignacio, Rachel Bender
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed
2
45
US, RoW
Glecaprevir/Pibrentasvir (G/P), Mavyret
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV Infection
05/23
08/23
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
NCT04983030: Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Active, not recruiting
1/2
36
US
Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS
Boris Juelg, MD PhD, Janssen Pharmaceuticals, Harvard School of Public Health (HSPH), National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
02/26
04/26
NCT05850728: First in Human Study of TLC-ART 101 (ACTU 2001)

Recruiting
1
16
US
TLC-ART
University of Washington, National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
10/25
12/25
Phone, UW Positive Research Screening
NCT05850728: First in Human Study of TLC-ART 101 (ACTU 2001)

Recruiting
1
16
US
TLC-ART
University of Washington, National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
10/25
12/25

Download Options